Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)

BACKGROUND: The efficacy of ixekizumab, an anti‐interleukin‐17A (anti‐IL‐17A) monoclonal IgG4 antibody, was demonstrated in moderate‐to‐severe psoriasis patients when administered via prefilled syringe (PFS). OBJECTIVE: To evaluate the effect of two drug delivery devices on the pharmacokinetics (PK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Callis Duffin, K., Bagel, J., Bukhalo, M., Mercado Clement, I.J., Choi, S.L., Zhao, F., Gill, A., Pangallo, B., Shuler, C., Mallbris, L., Jackson, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215575/
https://www.ncbi.nlm.nih.gov/pubmed/27500949
http://dx.doi.org/10.1111/jdv.13768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215575/
https://www.ncbi.nlm.nih.gov/pubmed/27500949
http://dx.doi.org/10.1111/jdv.13768

Ejemplares similares